BUPRENORPHINE HYDROCHLORIDE

Post-LOE

buprenorphine hydrochloride

Teva

ANDAINJECTIONINJECTABLE

Approved

Jan 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BUPRENORPHINE HYDROCHLORIDE (buprenorphine hydrochloride) by Teva is clinical pharmacology mechanism of action buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa- opioid receptor. Approved for pain severe enough to require an opioid analgesic, for which alternate treatments are inadequate. First approved in 2025.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa- opioid receptor. One unusual property of buprenorphine hydrochloride injection observed in vitro studies is its very slow rate of dissociation from its receptor.…

Worked on BUPRENORPHINE HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

BUPRENORPHINE HYDROCHLORIDE

Mechanism of Action

Indications (2)